1
|
Haffouz A, Elleuch H, Khemakhem B, Ben Amor I, Jerbi A, Gargouri J, Sahli E, Mhadhbi N, Ghalla H, Rezgui F, Gargouri A, HadjKacem B. Antiplatelet activity and toxicity profile of novel phosphonium salts derived from Michael reaction. Eur J Pharm Sci 2024; 194:106692. [PMID: 38181870 DOI: 10.1016/j.ejps.2024.106692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/30/2023] [Accepted: 01/02/2024] [Indexed: 01/07/2024]
Abstract
In this work, five novel phosphonium salts derived from the Michael reaction were screened for their antiplatelet activity. Our findings revealed that compounds 2a, 2b, 2c, and 2d significantly inhibit platelet aggregation triggered by ADP or collagen (P < 0.001). Notably, compound 2c inhibited the arachidonic acid pathway (P < 0.001). Moreover, the selected compounds reduce CD62-P expression and inhibit GPIIb/IIIa activation. The interactions of the active compounds with their targets, ADP and collagen receptors, P2Y12 and GPVI respectively were investigated in silico using molecular docking studies. The results revealed a strong affinity of the active compounds for P2Y12 and GPVI. Additionally, cytotoxicity assays on platelets, erythrocytes, and human embryonic kidney HEK293 cells showed that compounds 2a, 2c and 2d were non-toxic even at high concentrations. In summary, our study shows that phosphonium salts can have strong antiplatelet power and suggests that compounds 2a, 2c and 2d could be promising antiplatelet agents for the management of cardiovascular diseases.
Collapse
Affiliation(s)
- Asma Haffouz
- Laboratory of Molecular Biotechnology of Eucaryotes, Centre of Biotechnology of Sfax, University of Sfax, B.P 1177, 3018, Sfax, Tunisia
| | - Haitham Elleuch
- Laboratory of Organic Chemistry, Faculty of Sciences, University Campus, 2092, University of Tunis El Manar, Tunis, Tunisia
| | - Bassem Khemakhem
- Laboratory of Plant Biotechnology, Sfax Faculty of Sciences, BP 1171, University of Sfax, 3038 Sfax, Tunisia
| | - Ikram Ben Amor
- Laboratory of Hematology (LR19SP04), Medical Faculty of Sfax. University of Sfax, Magida Boulila Avenue, 3029 Sfax, Tunisia
| | - Amira Jerbi
- Laboratory of Hematology (LR19SP04), Medical Faculty of Sfax. University of Sfax, Magida Boulila Avenue, 3029 Sfax, Tunisia
| | - Jalel Gargouri
- Laboratory of Hematology (LR19SP04), Medical Faculty of Sfax. University of Sfax, Magida Boulila Avenue, 3029 Sfax, Tunisia
| | - Emna Sahli
- Analytical service provider unit, Centre of Biotechnology of Sfax, University of Sfax, 3018, Sfax, Tunisia
| | - Noureddine Mhadhbi
- Laboratory Physico Chemistry of the Solid State, Department of Chemistry, Faculty of Sciences, University of Sfax, BP 1171, 3000 Sfax, Tunisia; University of Monastir, Preparatory Institute for Engineering Studies of Monastir, 5019 Monastir, Tunisia
| | - Houcine Ghalla
- Quantum Physics and Statistic Laboratory, Faculty of Sciences, University of Monastir, Monastir, 5000, Tunisia
| | - Farhat Rezgui
- Laboratory of Organic Chemistry, Faculty of Sciences, University Campus, 2092, University of Tunis El Manar, Tunis, Tunisia
| | - Ali Gargouri
- Laboratory of Molecular Biotechnology of Eucaryotes, Centre of Biotechnology of Sfax, University of Sfax, B.P 1177, 3018, Sfax, Tunisia
| | - Basma HadjKacem
- Laboratory of Molecular Biotechnology of Eucaryotes, Centre of Biotechnology of Sfax, University of Sfax, B.P 1177, 3018, Sfax, Tunisia; Department of Life Sciences, Faculty of Sciences of Gafsa, University of Gafsa, Gafsa, Tunisia.
| |
Collapse
|
2
|
Liu X, Wang S, Cui L, Zhou H, Liu Y, Meng L, Chen S, Xi X, Zhang Y, Kang W. Flowers: precious food and medicine resources. FOOD SCIENCE AND HUMAN WELLNESS 2023. [DOI: 10.1016/j.fshw.2022.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Pennings GJ, Reddel CJ, Chen VM, Gnanenthiran SR, Kritharides L. Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Front Cardiovasc Med 2023; 9:1104744. [PMID: 36741844 PMCID: PMC9892722 DOI: 10.3389/fcvm.2022.1104744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 12/30/2022] [Indexed: 01/20/2023] Open
Abstract
Colchicine has been demonstrated to reduce cardiovascular death, myocardial infarction (MI), ischemic stroke, and ischemia-driven coronary revascularization in people with coronary artery disease (CAD). These reductions were observed even in patients already taking antiplatelet therapy. As well as having anti-inflammatory effects, colchicine demonstrates antiplatelet effects. We propose that colchicine's antiplatelet effects primarily target collagen-induced platelet activation via the collagen receptor, glycoprotein (GP)VI, which is critical for arterial thrombosis formation. In settings such as stroke and MI, GPVI signaling is upregulated. We have demonstrated in vitro that therapeutic concentrations of colchicine lead to a decrease in collagen-induced platelet aggregation and alter GPVI signaling. Clinical studies of colchicine given for 6 months lead to a significant reduction in serum GPVI levels in CAD patients, which may ameliorate thrombotic risk. Future evaluation of the effects of colchicine in clinical trials should include assessment of its effects on collagen-mediated platelet activation, and consideration be given to quantifying the contribution of such antiplatelet effects additional to the known anti-inflammatory effects of colchicine.
Collapse
Affiliation(s)
- Gabrielle J. Pennings
- Vascular Biology Group, ANZAC Research Institute, The University of Sydney, Concord, NSW, Australia,Department of Cardiology, Concord Repatriation General Hospital, Concord, NSW, Australia
| | - Caroline J. Reddel
- Vascular Biology Group, ANZAC Research Institute, The University of Sydney, Concord, NSW, Australia
| | - Vivien M. Chen
- Department of Haematology, Concord Repatriation General Hospital, Concord, NSW, Australia,Platelet, Thrombosis Research Laboratory, ANZAC Research Institute, The University of Sydney, Concord, NSW, Australia
| | - Sonali R. Gnanenthiran
- Vascular Biology Group, ANZAC Research Institute, The University of Sydney, Concord, NSW, Australia,Department of Cardiology, Concord Repatriation General Hospital, Concord, NSW, Australia,The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia
| | - Leonard Kritharides
- Vascular Biology Group, ANZAC Research Institute, The University of Sydney, Concord, NSW, Australia,Department of Cardiology, Concord Repatriation General Hospital, Concord, NSW, Australia,*Correspondence: Leonard Kritharides ✉
| |
Collapse
|
4
|
Liu G, Yuan Z, Tian X, Xiong X, Guo F, Lin Z, Qin Z. Pimpinellin Inhibits Collagen-induced Platelet Aggregation and Activation Through Inhibiting Granule Secretion and PI3K/Akt Pathway. Front Pharmacol 2021; 12:706363. [PMID: 34366861 PMCID: PMC8339208 DOI: 10.3389/fphar.2021.706363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 07/07/2021] [Indexed: 01/21/2023] Open
Abstract
Pimpinellin is a coumarin-like compound extracted from the root of Toddalia asiatica. Its effects on platelet function has not been investigated. This study found that pimpinellin pretreatment effectively inhibited collagen-induced platelet aggregation, but did not alter ADP- and thrombin-induced aggregation. Platelets pretreated with pimpinellin showed reduced α granule (CD62) level and secretion of dense granule (ATP release). Pimpinellin-treated platelets also exhibited decreased clot reaction and TxB2 production. Pimpinellin pretreatment suppressed adhesion and spreading of human platelets on the fibrinogen coated surface. Analysis of tail bleeding time of mice administered with pimpinellin (40 mg/kg) revealed that pimpinellin did not change tail bleeding time significantly, number of blood cells, and APTT and PT levels. Pimpinellin inhibited collagen-induced ex vivo aggregation of mice platelets. Immunoblotting results showed that pimpinellin suppressed collagen-induced phosphorylation of PI3K-Akt-Gsk3β and PKC/MAPK in platelets.
Collapse
Affiliation(s)
- Gang Liu
- School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.,Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.,Guizhou Provincial Key Laboratory of Pathogenesis and Drug Research on Common Chronic Diseases, Guizhou Medical University, Guiyang, China
| | - Zhaowei Yuan
- School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China
| | - Xiaoyun Tian
- School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China
| | - Xiuqin Xiong
- School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China
| | - Fang Guo
- School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China
| | - Zihan Lin
- Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China
| | - Zhen Qin
- School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China
| |
Collapse
|